Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus FLURBIPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus FLURBIPROFEN.
FENOPROFEN CALCIUM vs FLURBIPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis; nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
Oral: 50-100 mg every 6-8 hours; maximum 300 mg/day. Ophthalmic: 1 drop every 30 minutes starting 2 hours before surgery, then 1 drop every 4-6 hours for 24-48 hours post-surgery.
None Documented
None Documented
Clinical Note
moderateFlurbiprofen + Gatifloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateFlurbiprofen + Rosoxacin
"Flurbiprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateFlurbiprofen + Levofloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateFlurbiprofen + Trovafloxacin
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life: 3-4 hours (healthy adults) in short-term use; prolonged to 6-12 hours in elderly or renal impairment.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Renal: 70% as conjugated metabolites (e.g., glucuronides) and <5% unchanged; biliary/fecal: 30%, with enterohepatic circulation.
Category C
Category D/X
NSAID
NSAID
"Flurbiprofen may increase the neuroexcitatory activities of Trovafloxacin."